The second most common breast carcinoma, invasive lobular carcinoma, accounts for approximately 15% of tumors of breast origin. Its incidence has increased in recent times due in part to hormone replacement therapy and improvement in diagnostic modalities. Although believed to arise from the same cell type as their ductal counterpart, invasive lobular carcinomas (ILCs) are a distinct entity with different regulating genetic pathways, characteristic histologies, and different biology. The features most unique to lobular carcinomas include loss of E-Cadherin leading to discohesion and formation of a characteristic single file pattern on histology. Because most of these tumors exhibit estrogen receptor positivity and Her2 neu negativity, endocrine therapy has predominated to treat these tumors. However novel treatments like CDK4/6 inhibitors have shown importance and antibody drug conjugates may be instrumental considering newer categories of Her 2 Low breast tumors. In this narrative review, we explore multiple pathological aspects and translational features of this unique entity. In addition, due to advancement in technologies like spatial transcriptomics and other hi-plex technologies, we have tried to enlist upon the characteristics of the tumor microenvironment and the latest associated findings to better understand the new prospective therapeutic options in the current era of personalized treatment.
浸润性小叶癌作为第二常见的乳腺癌类型，约占乳腺来源肿瘤的15%。近年来其发病率有所上升，部分原因与激素替代疗法及诊断手段的改进有关。尽管被认为与导管癌源自相同细胞类型，浸润性小叶癌（ILCs）在调控基因通路、特征性组织学表现及生物学行为方面均具有独特性。该肿瘤最显著的特征包括E-钙黏蛋白缺失导致的细胞黏附丧失，以及组织学上特征性的单行排列模式。由于此类肿瘤多表现为雌激素受体阳性及Her2 neu阴性，内分泌治疗已成为主要治疗手段。然而，CDK4/6抑制剂等新型疗法已显示出重要价值，且考虑到Her2低表达型乳腺癌新分类的出现，抗体药物偶联物可能发挥关键作用。本文通过叙述性综述，系统探讨了这一特殊类型肿瘤的多重病理学特征与转化医学特性。此外，借助空间转录组学等高通量技术的发展，我们尝试归纳肿瘤微环境特征及相关最新发现，以深入理解当前个体化治疗时代的新型潜在治疗策略。
Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights
肿瘤(癌症)患者之家